Gender differences among persons entering medication treatment for opioid use disorder in the community.
Journal
The American journal on addictions
ISSN: 1521-0391
Titre abrégé: Am J Addict
Pays: England
ID NLM: 9208821
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
revised:
17
05
2022
received:
27
10
2021
accepted:
20
05
2022
pubmed:
3
6
2022
medline:
11
9
2022
entrez:
2
6
2022
Statut:
ppublish
Résumé
We evaluated gender differences among persons initiating medications for opioid use disorder (MOUD). Analyses of baseline assessments for a study evaluating the impact of MOUD on outcomes included: demographics, DSM-5 diagnoses, depression severity, quality of life (QoL), and medication history (N = 125). When compared to men, women had a greater prevalence of generalized anxiety and posttraumatic stress disorders; and worse psychological QoL. Women were less likely to be prescribed psychiatric medications. Women may benefit from tailored multidisciplinary programs with MOUD. This study identified that women with OUD seeking MOUD in the community had greater sedative hypnotic nonprescribed medication use and psychiatric comorbidity than men, all of which can contribute to poorer retention on MOUD and higher risk of morbidity and mortality. Thus, concurrent psychiatric disorder screening and treatment integrated with MOUD may improve retention on MOUD, opioid relapse and overdose for women.
Sections du résumé
BACKGROUND AND OBJECTIVES
We evaluated gender differences among persons initiating medications for opioid use disorder (MOUD).
METHODS
Analyses of baseline assessments for a study evaluating the impact of MOUD on outcomes included: demographics, DSM-5 diagnoses, depression severity, quality of life (QoL), and medication history (N = 125).
RESULTS
When compared to men, women had a greater prevalence of generalized anxiety and posttraumatic stress disorders; and worse psychological QoL. Women were less likely to be prescribed psychiatric medications.
DISCUSSION AND CONCLUSIONS
Women may benefit from tailored multidisciplinary programs with MOUD.
SCIENTIFIC SIGNIFICANCE
This study identified that women with OUD seeking MOUD in the community had greater sedative hypnotic nonprescribed medication use and psychiatric comorbidity than men, all of which can contribute to poorer retention on MOUD and higher risk of morbidity and mortality. Thus, concurrent psychiatric disorder screening and treatment integrated with MOUD may improve retention on MOUD, opioid relapse and overdose for women.
Identifiants
pubmed: 35652902
doi: 10.1111/ajad.13304
pmc: PMC9463117
mid: NIHMS1809905
doi:
Substances chimiques
Analgesics, Opioid
0
Buprenorphine
40D3SCR4GZ
Naltrexone
5S6W795CQM
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
390-395Subventions
Organisme : NIDA NIH HHS
ID : R61 DA047037
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA043337
Pays : United States
Organisme : NIA NIH HHS
ID : K24 AG042489
Pays : United States
Organisme : NIDA NIH HHS
ID : K02 DA032322
Pays : United States
Informations de copyright
© 2022 American Academy of Addiction Psychiatry.
Références
J Subst Abuse Treat. 2001 Jan;20(1):53-7
pubmed: 11239728
Addiction. 2020 Nov;115(11):2079-2088
pubmed: 32279394
Clin Psychol Rev. 2018 Dec;66:12-23
pubmed: 29174306
Int J Addict. 1985 Aug;20(8):1143-62
pubmed: 4077316
Curr Opin Psychiatry. 2017 Jul;30(4):238-246
pubmed: 28426545
Obstet Gynecol. 2019 Jun;133(6):1131-1140
pubmed: 31135726
J Addict Med. 2020 Sep/Oct;14(5):364-366
pubmed: 32011410
Mol Psychiatry. 2019 Dec;24(12):1868-1883
pubmed: 29934549
Clin Psychol Rev. 2011 Apr;31(3):328-41
pubmed: 21382538
Addiction. 2002 Sep;97(9):1183-94
pubmed: 12199834
Am J Addict. 2018 Sep;27(6):465-470
pubmed: 30106494
Lancet. 2018 Jul 7;392(10141):9-11
pubmed: 30047402
Addiction. 2005 Jul;100(7):981-9
pubmed: 15955014
Psychol Med. 1998 May;28(3):551-8
pubmed: 9626712
J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57
pubmed: 9881538
Drug Alcohol Depend. 2015 Mar 1;148:217-20
pubmed: 25630964
JAMA Psychiatry. 2017 Dec 1;74(12):1197-1205
pubmed: 29049469
Am J Addict. 2000 Spring;9(2):145-53
pubmed: 10934576
Contemp Clin Trials Commun. 2021 Jan 06;21:100704
pubmed: 33490708
Acad Emerg Med. 2006 May;13(5):543-7
pubmed: 16641481
Curr Psychiatry Rep. 2020 Oct 31;22(12):76
pubmed: 33128093
Health Justice. 2014 Oct 29;2(11):
pubmed: 25606368
J Subst Abuse Treat. 2013 Jul;45(1):38-43
pubmed: 23313145
J Am Acad Child Adolesc Psychiatry. 2011 Jun;50(6):543-53
pubmed: 21621138
Subst Abus. 2021;42(4):905-911
pubmed: 33750285
J Clin Psychiatry. 2006 Jul;67(7):1062-73
pubmed: 16889449
Ann Ist Super Sanita. 2016 Apr-Jun;52(2):184-9
pubmed: 27364392
J Subst Abuse Treat. 2020 Aug;115:108040
pubmed: 32600627
Lancet. 2018 Jan 27;391(10118):309-318
pubmed: 29150198
Drug Alcohol Depend. 2004 Jun 11;74(3):265-72
pubmed: 15194204
Drug Alcohol Depend. 2014 Dec 1;145:127-33
pubmed: 25454410
N Engl J Med. 2006 Jul 27;355(4):365-74
pubmed: 16870915
Lancet. 2019 Feb 23;393(10173):778-790
pubmed: 30792007
Drug Alcohol Depend. 2015 Nov 1;156:47-56
pubmed: 26374990
Addiction. 2004 Aug;99(8):978-88
pubmed: 15265095
Forensic Sci Int. 2001 Sep 15;121(1-2):65-9
pubmed: 11516889
MMWR Morb Mortal Wkly Rep. 2019 Jan 11;68(1):1-5
pubmed: 30629574
Drug Alcohol Depend. 2007 Jan 5;86(1):1-21
pubmed: 16759822
Am J Drug Alcohol Abuse. 2011 Sep;37(5):313-23
pubmed: 21854273